Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

TRADE NEWS: Agilent Technologies Introduces Microarray for Rapid Screening of Aneuploidy in Single Cells from Embryos

A, BIOGY

Agilent Technologies Inc. (NYSE: A) today introduced the GenetiSure Pre-Screen Kit, a high-throughput oligonucleotide microarray for screening aneuploidy and other genomic aberrations in the 5- to 10-Mb range from single cells in three- and five-day embryos.

Agilent’s kit allows for a turnaround time of less than eight hours from DNA extraction to data analysis—an industry first. The kit consists of a microarray that can run up to 14 samples and two reference samples simultaneously, so more embryos can be screened without significantly increasing costs.

“No other array platform currently has this high-throughput capacity, with less than eight hours turn-around time, with this resolution,” said Dr. Richard Choy, Ph.D., director of the Pre-Implantation Genetic Diagnosis Center and associate professor of the Department of Obstetrics and Gynecology at the Chinese University of Hong Kong.

“We are cautious about the overall cost and value of our screening,” Choy said. “We are able to use the capacity of Agilent’s kit to address this price sensitivity, and it will be key technology in our work.”

Agilent’s GenetiSure prescreen kit was developed based on a protocol designed by Ali Hellani, Ph.D., director of the Viafet Genomic Center in Dubai.

“Agilent’s microarray data can show small, few-megabase microdeletions that are very difficult to detect at a single-cell level,” Hellani said.

The GenetiSure Pre-Screen array is based on Agilent’s market-leading technology for high-resolution oligonucleotide comparative genomic hybridization. The kit contains all necessary reagents to enable whole-genome amplification and labeling of single cells. The microarray is compatible with Agilent’s CytoGenomics software (version 3.0 or higher) for easy data analysis.

To learn more about the GenetiSure Pre-Screen Kit, visit www.agilent.com/genomics/genetisure/prescreen.

Agilent’s GenetiSure Pre-Screen Kit is for research use only, not for use in diagnostic procedures.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of $4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

EDITORIAL CONTACT:
for Agilent Technologies
Jennifer Mann, +1 303-357-2391
jmann@webershandwick.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today